Research map: First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

Back to the article

Papers in this map

  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer · Martin Reck · 2016 · 10309 citations · Cited by this paper
  2. Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis · Jialin Su · 2025 · 52 citations · Cites this paper
  3. HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · 2026 · Related
  4. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer · H. Borghaei · 2015 · 9564 citations · Cited by this paper
  5. PD-1/PD-L1 and DNA Damage Response in Cancer · Mateusz Kciuk · 2023 · 44 citations · Cites this paper
  6. Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · 2026 · Related
  7. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial · Roy S. Herbst · 2015 · 6592 citations · Cited by this paper
  8. Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study · Helga Helseth Hektoen · 2024 · 24 citations · Cites this paper
  9. Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · 2026 · Related
  10. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer · Edward B. Garon · 2015 · 6314 citations · Cited by this paper
  11. Metastatic brain tumors: from development to cutting‐edge treatment · Guilong Tanzhu · 2024 · 17 citations · Cites this paper
  12. Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · 2026 · Related
  13. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden · Matthew David Hellmann · 2018 · 3187 citations · Cited by this paper
  14. Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer · Veronika Pelicon · 2023 · 16 citations · Cites this paper
  15. Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · 2026 · Related
  16. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% · Martin Reck · 2021 · 1185 citations · Cited by this paper
  17. Research advances in immune checkpoint drugs for non-small cell lung cancer · Yue Shen · 2023 · 11 citations · Cites this paper
  18. Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · 2026 · Related
  19. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer · Manash Shankar Chatterjee · 2016 · 173 citations · Cited by this paper
  20. Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia · Filip Marković · 2025 · 9 citations · Cites this paper
  21. Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · 2026 · Related
  22. Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer · Giulia Pasello · 2020 · 142 citations · Cited by this paper
  23. The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study · Filip Marković · 2025 · 9 citations · Cites this paper
  24. Untitled · Cited by this paper
  25. Three-Year Overall Survival of Patients With Advanced Non–Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study) · Chantal Decroisette · 2023 · 6 citations · Cites this paper
  26. Untitled · Cited by this paper
  27. The safety and efficacy of anti-PD-1/PD-L1 monoclonal antibodies for lung cancer brain metastasis: a systematic review and meta-analysis on brain metastasis · Pouria Delbari · 2025 · 6 citations · Cites this paper
  28. Untitled · Cited by this paper
  29. Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia · Chin Hang Yiu · 2026 · 6 citations · Cites this paper
  30. Untitled · Cited by this paper
  31. Immune Checkpoint Inhibition in Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Emerging Mechanisms and Personalized Clinical Strategies · Nicola Joseph Nasser · 2025 · 5 citations · Cites this paper
  32. Untitled · Cited by this paper
  33. Lung cancer with brain metastases remaining in continuous complete remission due to pembrolizumab and temozolomide: a case report · Xianmin Zhu · 2022 · 4 citations · Cites this paper
  34. Untitled · Cited by this paper
  35. Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer · Helene Doubre · 2023 · 3 citations · Cites this paper
  36. Untitled · Cited by this paper
  37. Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan · Taher Abu Hejleh · 2024 · 3 citations · Cites this paper
  38. Untitled · Cited by this paper
  39. Brain Metastases as Inaugural Sign of Non-Small Cell Lung Carcinoma: Case Series and Review of Literature · Alexandra Pușcașu · 2024 · 2 citations · Cites this paper

Source: OpenAlex (CC0)